Evidence map›Paper›PMID 25124676›Full record

ArticleLupus2015

Anti-C1q antibodies in systemic lupus erythematosus.

A-M Orbai, L Truedsson, G Sturfelt, O Nived, H Fang, G S Alarcón, C Gordon, Jt Merrill, P R Fortin, I N Bruce and 43 more

2 registry-linked trialsOpen access · greenAbstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Lupus, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
9.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02625831 completednot on this map

Association Between the Presence of Autoantibodies Targeting Ficolin-3 and Active Nephritis in Patients With Systemic Lupus Erythematosus

TypeobservationalSponsorUniversity Hospital, GrenobleRan2012 to 2014Enrolled213ConditionsLupus Erythematosus, SystemicArmsBiological analysis
NCT03063281 completednot on this map

Association Between the Presence of Autoantibodies Targeting Ficolin-2 and Active Nephritis in Patients With Systemic Lupus Erythematosus

TypeobservationalSponsorUniversity Hospital, GrenobleRan2012 to 2015Enrolled213ConditionsLupus Erythematosus, SystemicArmsBIological analysis
3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it, 110 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Article
  4. C1q CIC in Lupus Nephritis: An Analysis of 883 Patients.International journal of medical sciences · 2026
    Article
  5. Article
  6. Lupus nephritis.Nature reviews. Disease primers · 2025
    Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Lupus nephritis.Nature reviews. Disease primers · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

53 authors at 20 institutions in 10 countries.

A-M OrbaiDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
L TruedssonDepartment of Laboratory Medicine, Section of Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden.
G SturfeltDepartment of Rheumatology, Skåne University Hospital, Lund, Sweden.
O NivedDepartment of Rheumatology, Skåne University Hospital, Lund, Sweden.
H FangDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
G S AlarcónDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
C GordonRheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences University of Birmingham, Birmingham, UK.
Jt MerrillDepartment of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA.
P R FortinDivision of Rheumatology, Department of Medicine, Centre Hospitalier Universitaire (CHU) de Québec Axe Maladies Infectieuses et Immunitaires, CRCHU de Québec, Université Laval, Quebec City, Quebec, Canada.
I N BruceArthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, UK NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, UK.
D A IsenbergCentre for Rheumatology, Research Division of Medicine, London, UK.
D J WallaceCedars-Sinai Medical Center, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
R Ramsey-GoldmanNorthwestern University, Feinberg School of Medicine, Chicago, IL, USA.
S-C BaeDepartment of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea.
J G HanlyDivision of Rheumatology, Departments of Medicine and Pathology Capital Health and Dalhousie University, Halifax, Nova Scotia, Canada.
J Sanchez-GuerreroMount Sinai Hospital and University Health Network, Toronto, Ontario, Canada.
A E ClarkeDivisions of Clinical Epidemiology and Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada.
C B AranowFeinstein Institute for Medical Research, Manhasset, NY, USA.
S ManziDepartment of Medicine, Division of Rheumatology, Allegheny Singer Research Institute, Allegheny General Hospital, Pittsburgh, PA, USA.
M B UrowitzToronto Western Hospital Toronto, Ontario, Canada.
D D GladmanToronto Western Hospital Toronto, Ontario, Canada.
K C KalunianDivision of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, USA.
M I CostnerNorth Dallas Dermatology Associates, Dallas, TX, USA.
V P WerthPhiladelphia VA Medical Center and University of Pennsylvania, Philadelphia, PA, USA.
A ZomaLanarkshire Centre for Rheumatology and Hairmyres Hospital, East Kilbride, UK.
S BernatskyDivisions of Clinical Epidemiology and Rheumatology, McGill University Health Centre, Montreal, Quebec, Canada.
G Ruiz-IrastorzaAutoimmune Diseases Research Unit, Hospital Universitario Cruces Universidad del Pais Vasco, Barakaldo, Spain.
M A KhamashtaRayne Institute and St Thomas' Hospital London, UK.
S JacobsenRigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
J P BuyonNew York University, New York, NY, USA.
P MaddisonYsbyty Gwynedd, Bangor, UK.
M A DooleyUniversity of North Carolina, Chapel Hill, NC, USA.
R F Van VollenhovenKarolinska University Hospital, Stockholm, Sweden.
E GinzlerState University of New York, Downstate Medical Center, Brooklyn, NY, USA.
T StollKantonsspital Schaffhausen, Schaffhausen, Switzerland.
C PeschkenUniversity of Manitoba Winnipeg, Manitoba, Canada.
J L JorizzoWake Forest University, Winston-Salem, NC, USA.
J P CallenUniversity of Louisville, Louisville, KY, USA.
S S LimEmory University, Atlanta, GA, USA.
B J FesslerDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
M InancDivision of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey.
D L KamenMedical University of South Carolina, Charleston, SC, USA.
A RahmanNIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, UK.
K SteinssonLandspitali University Hospital, Reykjavik, Iceland.
A G FranksNew York University, New York, NY, USA.
L SiglerDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
S HameedDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
N PhamDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
R BreyUniversity of Texas Health Science Center, San Antonio, TX, USA.
M H WeismanCedars-Sinai Medical Center, Los Angeles, CA, USA.
G McGwinDepartment of Medicine, Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, USA.
L S MagderDepartment of Epidemiology and Public Health, University of Maryland, Baltimore, MD, USA.
M PetriDivision of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA MPetri@jhmi.edu.
Johns Hopkins Medicine · USJohns Hopkins University · USUniversity of Alabama at Birmingham · USCedars-Sinai Medical Center · USMcGill University Health Centre · CANew York University · USSkåne University Hospital · SEToronto Western Hospital · CAAllegheny-Singer Research Institute · USBritish Society for Rheumatology · GBDalhousie University · CAEmory University · USFeinstein Institute for Medical Research · USHairmyres Hospital · GBHanyang University Seoul Hospital · KRIstanbul University · TRKarolinska University Hospital · SELund University · SEManchester Academic Health Science Centre · GBMedical University of South Carolina · US

Funding

Northwestern University Clinical and Translational Science Institute (NUCATS)UL1TR001422 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI D'AQUILA, RICHARD · 2015 to 2023
$56.8M
Lupus CohortR01AR043727 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 1997 to 2015
$8.2M
Multidisciplinary Rheumatology Training ProgramT32AR048522 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI CLIFTON O BINGHAM, LIVIA A CASCIOLA-ROSEN · 2003 to 2026
$6.4M
Revision of ACR Classification Criteria for Systemic Lupus ErythematosusU01AR051871 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 2005 to 2007
$500k
Revision of ACR Classification Criteria for SLER01AR051871 · NIAMS · JOHNS HOPKINS UNIVERSITY · PI PETRI, MICHELLE A · 2004 to 2004
$245k
Department of Health MANMKBRU-2012-1NCATS NIH HHS UL1 TR001422NIAMS NIH HHS R01 AR043727NIAMS NIH HHS R01 AR051871NIAMS NIH HHS T32 AR048522NIAMS NIH HHS T32AR048522NIAMS NIH HHS U01 AR051871
6 · The paper itself

Abstract

objectiveAnti-C1q has been associated with systemic lupus erythematosus (SLE) and lupus nephritis in previous studies. We studied anti-C1q specificity for SLE (vs rheumatic disease controls) and the association with SLE manifestations in an international multicenter study.

methodsInformation and blood samples were obtained in a cross-sectional study from patients with SLE (n = 308) and other rheumatologic diseases (n = 389) from 25 clinical sites (84% female, 68% Caucasian, 17% African descent, 8% Asian, 7% other). IgG anti-C1q against the collagen-like region was measured by ELISA.

resultsPrevalence of anti-C1q was 28% (86/308) in patients with SLE and 13% (49/389) in controls (OR = 2.7, 95% CI: 1.8-4, p < 0.001). Anti-C1q was associated with proteinuria (OR = 3.0, 95% CI: 1.7-5.1, p < 0.001), red cell casts (OR = 2.6, 95% CI: 1.2-5.4, p = 0.015), anti-dsDNA (OR = 3.4, 95% CI: 1.9-6.1, p < 0.001) and anti-Smith (OR = 2.8, 95% CI: 1.5-5.0, p = 0.01). Anti-C1q was independently associated with renal involvement after adjustment for demographics, ANA, anti-dsDNA and low complement (OR = 2.3, 95% CI: 1.3-4.2, p < 0.01). Simultaneously positive anti-C1q, anti-dsDNA and low complement was strongly associated with renal involvement (OR = 14.9, 95% CI: 5.8-38.4, p < 0.01).

conclusionsAnti-C1q was more common in patients with SLE and those of Asian race/ethnicity. We confirmed a significant association of anti-C1q with renal involvement, independent of demographics and other serologies. Anti-C1q in combination with anti-dsDNA and low complement was the strongest serological association with renal involvement. These data support the usefulness of anti-C1q in SLE, especially in lupus nephritis.

Indexed as

AdultAntibodies, AntinuclearCase-Control StudiesComplement C1qComplement System ProteinsCross-Sectional StudiesDNAFemaleHumansLupus Erythematosus, SystemicLupus NephritisMaleMiddle AgedProteinuriaRheumatic DiseasesSensitivity and SpecificityAntibodies, AntinuclearComplement C1qComplement System ProteinsDNAAnti-dsDNA antibodiesrenal lupussystemic lupus erythematosus

Identifiers

PMID25124676
PMCPMC4268323
OpenAlexW1975785785

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.